Related Experiment Video

Updated: May 23, 2025

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
06:51

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

2.7K

Histone chaperones as potential epidrug targets against cancer

Sonam Malik1, Pramod Kumar2, Chander Prakash Yadav2

  • 1Department of Biotechnology, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India.

Nucleosides, Nucleotides & Nucleic Acids
|March 10, 2025
PubMed

Insights

Targeting histone chaperones offers a new strategy against cancer drug resistance. RBBP4 is identified as a key therapeutic target for developing novel epigenetic drugs to improve cancer treatment efficacy.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Epigenetic modifications are vital in cancer development and drug resistance.
  • Histone chaperones are implicated in cancer due to compensatory mechanisms.
  • Targeting epigenetic regulators (epidrugs) is a promising therapeutic strategy.

Purpose of the Study:

  • To identify potential epidrug targets among histone chaperones.
  • To analyze histone chaperone interactions and their role in cancer.
  • To find novel therapeutic interventions for overcoming cancer drug resistance.

Main Methods:

  • Enrichment and network analyses of histone chaperone interactions.
  • Identification of key hub proteins within histone chaperone networks.
  • Druggability prediction of identified protein targets.

Main Results:

  • Network analysis revealed HSP90AB1, RBBP4, NPM1, DAXX, and SET as key histone chaperone hub proteins.
  • RBBP4 emerged as a prime candidate due to its association with oncogenesis and forming the largest protein cluster.
  • Druggability assessment indicated RBBP4 as the most promising target, with Ritonavir as a potential epidrug.

Conclusions:

  • Histone chaperones, especially RBBP4, are promising targets for novel cancer epidrugs.
  • Understanding histone chaperone networks provides a foundation for developing effective cancer therapies.
  • Targeting RBBP4 could offer a new approach to overcome cancer drug resistance.
Keywords:
CancerCancer BiologyChemotherapyEpidrugsEpigenetic RegulationsHistone VariantsHistone chaperonesNetwork BiologyRBBP4

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K
Intracellular Refolding Assay07:18

Intracellular Refolding Assay

Published on: January 24, 2012

14.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.3K
DNA Helicases00:55

DNA Helicases

DNA unwinding helicase enzymes are a type of motor protein. Motor proteins can translocate along filaments or polymers using energy generated from ATP hydrolysis. Helicases are involved in all the important cellular processes where DNA unwinding is required, such as DNA replication, repair, recombination, and transcription. They are present in all living organisms, but vary in their structure, function, and mechanism of action. For example, in prokaryotes, DnaB helicase binds and translocates...
21.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K